Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173338 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
A Phase 1 study, sponsored by Augusta University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04173338: Clinical Trial Phase 1 study, sponsored by Augusta University.
NCT04173338 is a Phase 1 study that was terminated before completion, run by Augusta University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04173338, a Phase 1 study, was terminated before completion, sponsored by Augusta University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
Primary Outcome
Dose-limiting toxicity of grade 3 or higher using CTCAE 5
Interventions
- DRUG Pemetrexed
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2022-03-28 |
| Phase | Phase 1 |
Why NCT04173338 stopped before completion
NCT04173338 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT04173338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04173338 about?
NCT04173338 is a clinical study titled "Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma". This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.
What is the current status of trial NCT04173338?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2020-01-23. Estimated completion is 2022-03-28.
What interventions are being tested in trial NCT04173338?
The interventions under investigation include: Pemetrexed (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04173338?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04173338's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI